# EDGAR Filing Document

**Accession Number:** 0001597553
**File Stem:** 0001104659-25-076215
**Filing Date:** 2025-8
**Character Count:** 2749
**Document Hash:** d6864197350b76151260ab1cf1a5c31f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-076215.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001104659-25-076215

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**EFFECTIVENESS DATE**: 20250811

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sage Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001597553
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36544
- **FILM NUMBER:** 251202800

**BUSINESS ADDRESS:**
- **STREET 1:** 55 CAMBRIDGE PARKWAY
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-299-8380

**MAIL ADDRESS:**
- **STREET 1:** 55 CAMBRIDGE PARKWAY
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 15** 

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

**Commission File Number: 001-36544** 

**Sage Therapeutics, Inc.** 

**(Exact name of registrant as specified in its charter)** 

**55 Cambridge Parkway**

**Cambridge, MA 02142**

**(617) 299-8380**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common Stock, par value $0.0001 per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ⌧ |
| Rule 12g-4(a)(2) | ¨ |
| Rule 12h-3(b)(1)(i) | x |
| Rule 12h-3(b)(1)(ii) | ¨ |
| Rule 15d-6 | ¨ |
| Rule 15d-22(b) | ¨ |

---

Approximate number of holders of record as of the certification or notice date: One (1)

Pursuant to the requirements of the Securities Exchange Act of 1934, Sage Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **SAGE THERAPEUTICS, INC.** | **SAGE THERAPEUTICS, INC.** |
| Date: August 11, 2025 | By: | /s/ Jack A. Khattar |
|  |  | Name: Jack A. Khattar |
|  |  | Title: President and Treasurer |

---